Fairvalue-Calculator Fairvalue-Calculator
EN DE

OZYMF (OZYMF) Fair Value & Analysis

Healthcare · US · Market cap $3.7M

Price$90.00
Fair Value$381.90
Upside+324.3%
Quality95/100
Evidence: Low Range $252.05 – $477.37

Fair value as of: Jun 25, 2026

Analysis

OZYMF (OZYMF) currently trades at $90.00, while our model-based Fair Value estimate is $381.90 — implying the stock looks roughly 324.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. Strategic Partners A/S was incorporated in 2009 and is based in Herlev, Denmark.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is OZYMF (OZYMF) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $381.90 versus a price of $90.00 — about +324% (undervalued). Model-based estimate, not financial advice.
What is the fair value of OZYMF?
Our 21-model fair value for OZYMF is $381.90 (as of Jun 25, 2026), built from audited fundamentals. The current price is $90.00.
What is the quality score of OZYMF?
OZYMF has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.